new gi intoler data vumer point right direct
stake remain high tecfidera ipr pend
earlier morn announc updat interim
data on-going open-label pivot trial vumer diroximel fumar
ms showcas detail consortium
multipl sclerosi center later today poster new data
show gi ae incid rate tecfidera trial one-year
treatment period discontinu rate due gi
compar favor collect real world discontinu rate associ
tecfidera vumer nda file via pathway vumer
gi tolerability-improv version tecfidera accept februari
assign pdufa definit rate
biogen current conduct head-to-head gi toler studi tecfidera
evolv data expect later view vumer particularli
import ms franchis backdrop buy pt
mylan institut ipr rais stake vumer month februari
mylan ipr cover patent mg dose institut signal
pto believ reason chanc one claim overturn
burden proof intern pto discuss preponder
evid like true said patent
scrutin twice found legitim patent new argument
includ baselin correct clinic trial data suggest
mg mg dose activ mg dose protect
obviou correct baselin field effect baselin imbal
imperfectli defin educ guess best remind prior art
need describ invent licens experi accordingli
put chanc model explicitli
idc btig estim compani document
million except per share amount
modest worri vumer sponsor seek approv base
approach drug design differ refer drug assum
fda buy-in issu weve seen approach
work past may rais bar precis pharmacokinet
equival activ moieti
what worth lose tecfidera base model tecfidera
zero start yield per share tecfidera zero start
yield per share tecfidera market split
assum deal start yield per share overal
dont see stake unaccept high
rate tg provid price target neutral rate stock
downgrad buy neutral null aducanumab readout march make appropri
updat model recogn lead compani neurolog space seem
significantli behind develop gene therapi like novarti nv rate voyag
buy therapeut get mab protein across blood brain barrier like denali approach
tecfidera front buy analyst timothi chiang ipr cover patent like continu
weigh next month
vs tecfidera ms data
psp data
cle/sl data
natalizumab epilepsi data
opicinumab ms data
parkinson diseas data
manag guidanc flat sale two year follow increas
base princip launch vumer
po adopt price point
spinraza conserv model attrit sale growth follow market
entri zolgensma risdiplam
zolgensma risdiplam significantli erod spinraza sale
neg ipr decis overturn tecfidera patent
potenti zolgensma risdiplam launch significantli erod spinraza sale
global
biopharmaceut compani
discov develop
commerci therapi
tecfidera tysabri avonex
plegridi headquart
cambridg found
thoma shrader harrison incom total research sell gener loss asset liabil held sale- amort acq intang fair valu adj contig collabor profit acquir in-process research restructur total oper interest incom expens incom incom tax equiti loss investe net tax- net incom non-controlling net incom total non- non- net incom ep non- ep weight averag share outstand
btig cover compani mention report
appendix analyst certif import disclosur
